Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO
Authors' conclusion
After 2 years of ETI, fasting glucose and HbA1c showed modest decreases. Glucose tolerance varied, and overall measures of insulin secretion did not deteriorate.
Study context
- Population
- People with cystic fibrosis (pwCF) ≥12 years with at least one F508del allele starting elexacaftor/tezacaftor/ivacaftor (ETI), 10 CF Centers
- Participants
- 79 completed baseline oral glucose tolerance tests (OGTTs)
- Exposure
- Before vs 12–18 and 24–30 months after ETI initiation
- Outcome
- Glycemia and insulin secretion
- Follow-up
- 24-30 months
Methodological detailssubstudy of PROMISE, multicenter, longitudinal mixed effects models, OGTTs completed: n = 68 at 12-18 months, n = 58 at 24-30 months
- Substudy of PROMISE
- Multicenter
- Longitudinal mixed effects models
- OGTTs completed: n = 68 at 12-18 months, n = 58 at 24-30 months
Main finding
As reported in the abstract
24-30 months
- Fasting glucose (mg/dL), median [IQR], baseline to 24-30 months, subset not on insulin (n = 61)
- 94 [92, 96] to 90 [88, 93], P = .02
- Hemoglobin A1c (HbA1c) decreased by 24-30 months
- 5.8% (5.6%, 5.9%) to 5.5% (5.4%, 5.6%), P < .001
- Insulin sensitivity (mU/L-1 min-1) decreased
- 8.4 [7.2, 9.5] vs 6.8 [5.8, 7.9], P = .03
- No changes in oral disposition index
- P = .14
Observational data: associations, not effects.
Original publication
Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO. J Clin Endocrinol Metab. Published 9 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →